Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 16/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 16/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 16/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 16/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 16/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 15/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 15/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 15/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 15/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8915063 | 0.84 | CA9 (0.58) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL7966915 | 0.83 | CA9 (0.54) | ALDH1A1 | |
| SCHEMBL7097969 | 0.83 | EPHX1 (0.64) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL8915308 | 0.82 | CA9 (0.60) | ALDH1A1L3MBTL1 | |
| SCHEMBL11519940 | 0.82 | ALDH1A1 (0.67) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL7901763 | 0.80 | KMT2A (0.71) | ALDH1A1MAPTMAPK1 | |
| SCHEMBL7904143 | 0.80 | KMT2A (0.71) | ALDH1A1MAPTMAPK1 | |
| SCHEMBL3901864 | 0.79 | KMT2A (0.64) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL5279007 | 0.79 | HDAC6 (0.75) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL5999075 | 0.79 | HDAC1 (0.74) | HDAC4HDAC1HDAC11HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357599-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2014-12-04 | — | — | US | disclosed |
| US-8871747-B2 | Urea and thiourea derivatives | TOPOTARGET A/S (DK) | 2014-10-28 | — | — | US | disclosed |
| US-20120010172-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | MCDERMOTT WILL & EMERY LLP (DC) | 2012-01-12 | — | — | US | disclosed |
| WO-2010023307-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | TOPOTARGET A/S (DK) | 2010-03-04 | — | — | WO | disclosed |
| EP-0984938-B1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | LEO PHARMA AS WITH SECONDARY N (DK) | 2003-09-10 | — | — | EP | disclosed |
| US-6346541-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS FOR BREAST, LUNG, AND SKIN CANCER | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010172-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | TST, NAMPT, NNMT | HDAC4 3226/4885HDAC1 1828/4885HDAC11 1576/4885 |
| US-20140357599-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | TST, NAMPT, NNMT | HDAC4 3226/4885HDAC1 1828/4885HDAC11 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.